These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 9439550)

  • 1. Multifactorial aspects of the treatment of the type II diabetic patient.
    Colwell JA
    Metabolism; 1997 Dec; 46(12 Suppl 1):1-4. PubMed ID: 9439550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results.
    Colwell JA
    Diabetes; 1996 Jul; 45 Suppl 3():S87-90. PubMed ID: 8674902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological strategies to prevent macrovascular disease in NIDDM.
    Colwell JA
    Diabetes; 1997 Sep; 46 Suppl 2():S131-4. PubMed ID: 9285515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus.
    Palumbo PJ
    J Diabetes Complications; 1998; 12(2):110-9. PubMed ID: 9559489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Glinide(s), sulfonylurea(s)].
    Arakawa M; Hirose T
    Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of glycemic control on the incidence of macrovascular complications of type 2 diabetes.
    Stern MP
    Arch Fam Med; 1998; 7(2):155-62. PubMed ID: 9519921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin for primary prevention of cardiovascular events in diabetes: still an open question.
    Nicolucci A
    JAMA; 2008 Nov; 300(18):2180-1. PubMed ID: 18997199
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.
    Cathelineau G; de Champvallins M; Bouallouche A; Lesobre B
    Metabolism; 1997 Dec; 46(12 Suppl 1):31-4. PubMed ID: 9439556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Postprandial hyperglycemia. Cardiovascular risks and new therapeutic strategies].
    Sjöholm A
    Lakartidningen; 2001 Feb; 98(9):937-40. PubMed ID: 11292972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes medications and cardiovascular disease: at long last progress.
    Lupsa BC; Inzucchi SE
    Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):87-93. PubMed ID: 29369916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.
    Fisher M
    Diabetes Obes Metab; 2015 Apr; 17(4):335-42. PubMed ID: 25155010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
    Paty BW
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term intervention studies of diabetic macroangiopathy in Japan and western countries].
    Sone H; Yamada N
    Nihon Rinsho; 2006 Nov; 64(11):2021-30. PubMed ID: 17087292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing macrovascular disease in patients with type 2 diabetes mellitus.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2003; 3(4):283-97. PubMed ID: 14728081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose control in diabetes: which target level to aim for?
    Laakso M; Cederberg H
    J Intern Med; 2012 Jul; 272(1):1-12. PubMed ID: 22321169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.
    Aryangat AV; Gerich JE
    Vasc Health Risk Manag; 2010 Mar; 6():145-55. PubMed ID: 20448799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 2 diabetes mellitus: prevention of macrovascular complications.
    Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.